Brief: I-Mab Announces Positive Phase 2 Data Of Lemzoparlimab In Combination With Azacitidine In Patients With Higher Risk Myelodysplastic Syndrome

NovaBridge Biosciences

10/09/2022 14:40

Sept 10 (Reuters) - I-Mab  IMAB.O :
    * ANNOUNCES POSITIVE PHASE 2 DATA OF LEMZOPARLIMAB IN
COMBINATION
WITH AZACITIDINE (AZA) IN PATIENTS WITH HIGHER RISK
MYELODYSPLASTIC SYNDROME AT ESMO 2022
    * LEMZOPARLIMAB DOES NOT REQUIRE PRIMING DOSING WITH NO
UNEXPECTED
SAFETY SIGNALS IN COMBINATION THERAPY WITH AZA
    * FOR SUBJECTS ACHIEVING CR, REMAINING GENE MUTATION
FREQUENCY
SUCH AS TP53, TET2 AND RUNX1 WERE SIGNIFICANTLY DECREASED

Source text for Eikon:  ID:nPn1tjWN5a 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))